vs
Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Creative Media & Community Trust Corp is the larger business by last-quarter revenue ($28.5M vs $18.6M, roughly 1.5× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -125.8%, a 191.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 3.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -8.5%).
Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CMCT vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.5M | $18.6M |
| Net Profit | $-11.4M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -125.6% | 56.3% |
| Net Margin | -125.8% | 65.7% |
| Revenue YoY | 3.6% | 1808.5% |
| Net Profit YoY | -11.4% | 376.5% |
| EPS (diluted) | $-3.89 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.5M | $18.6M | ||
| Q3 25 | $26.2M | $334.0K | ||
| Q2 25 | $29.7M | $1.4M | ||
| Q1 25 | $32.3M | $257.0K | ||
| Q4 24 | $27.5M | $977.0K | ||
| Q3 24 | $28.6M | $660.0K | ||
| Q2 24 | $34.4M | $736.0K | ||
| Q1 24 | $34.0M | $1.4M |
| Q4 25 | $-11.4M | $12.3M | ||
| Q3 25 | $-12.5M | $-8.6M | ||
| Q2 25 | $-9.0M | $-6.9M | ||
| Q1 25 | $-6.1M | $-5.4M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-10.4M | $-2.8M | ||
| Q2 24 | $-796.0K | $-14.5M | ||
| Q1 24 | $-3.7M | $411.0K |
| Q4 25 | -125.6% | 56.3% | ||
| Q3 25 | -47.7% | -2516.5% | ||
| Q2 25 | -30.3% | -701.0% | ||
| Q1 25 | -19.0% | -3350.2% | ||
| Q4 24 | -128.8% | — | ||
| Q3 24 | -36.9% | -1563.6% | ||
| Q2 24 | -1.6% | -1255.0% | ||
| Q1 24 | -10.7% | -692.5% |
| Q4 25 | -125.8% | 65.7% | ||
| Q3 25 | -47.5% | -2572.2% | ||
| Q2 25 | -30.3% | -504.8% | ||
| Q1 25 | -18.9% | -2097.7% | ||
| Q4 24 | -129.8% | — | ||
| Q3 24 | -36.3% | -425.5% | ||
| Q2 24 | -2.3% | -1964.4% | ||
| Q1 24 | -11.0% | 29.9% |
| Q4 25 | $-3.89 | $0.25 | ||
| Q3 25 | $-23.52 | $-0.17 | ||
| Q2 25 | $-18.94 | $-0.14 | ||
| Q1 25 | $-20.73 | $-0.11 | ||
| Q4 24 | $97.71 | — | ||
| Q3 24 | $-305.04 | $-0.06 | ||
| Q2 24 | $-98.64 | $-0.30 | ||
| Q1 24 | $-125.46 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.4M | $40.0M |
| Total DebtLower is stronger | $509.8M | — |
| Stockholders' EquityBook value | $265.4M | $49.4M |
| Total Assets | $859.2M | $59.0M |
| Debt / EquityLower = less leverage | 1.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.4M | $40.0M | ||
| Q3 25 | $17.3M | $37.9M | ||
| Q2 25 | $27.8M | $44.8M | ||
| Q1 25 | $19.8M | $40.6M | ||
| Q4 24 | $20.3M | $59.3M | ||
| Q3 24 | $18.5M | $68.8M | ||
| Q2 24 | $29.3M | $73.0M | ||
| Q1 24 | $21.3M | $80.2M |
| Q4 25 | $509.8M | — | ||
| Q3 25 | $527.8M | — | ||
| Q2 25 | $535.6M | — | ||
| Q1 25 | $512.7M | — | ||
| Q4 24 | $505.7M | — | ||
| Q3 24 | $478.3M | — | ||
| Q2 24 | $485.1M | — | ||
| Q1 24 | $472.8M | — |
| Q4 25 | $265.4M | $49.4M | ||
| Q3 25 | $281.9M | $36.4M | ||
| Q2 25 | $287.1M | $44.5M | ||
| Q1 25 | $293.0M | $50.5M | ||
| Q4 24 | $304.5M | $55.1M | ||
| Q3 24 | $321.0M | $58.5M | ||
| Q2 24 | $351.1M | $60.4M | ||
| Q1 24 | $369.9M | $74.1M |
| Q4 25 | $859.2M | $59.0M | ||
| Q3 25 | $871.8M | $51.1M | ||
| Q2 25 | $885.0M | $60.7M | ||
| Q1 25 | $882.3M | $67.9M | ||
| Q4 24 | $889.6M | $90.6M | ||
| Q3 24 | $868.0M | $99.0M | ||
| Q2 24 | $891.2M | $107.8M | ||
| Q1 24 | $887.5M | $118.3M |
| Q4 25 | 1.92× | — | ||
| Q3 25 | 1.87× | — | ||
| Q2 25 | 1.87× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.38× | — | ||
| Q1 24 | 1.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.8M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | $18.4M | ||
| Q3 25 | $3.7M | $-8.7M | ||
| Q2 25 | $-2.5M | $-7.5M | ||
| Q1 25 | $1.2M | $-7.5M | ||
| Q4 24 | $17.0M | $-24.0M | ||
| Q3 24 | $10.3M | $765.0K | ||
| Q2 24 | $3.9M | $-10.9M | ||
| Q1 24 | $1.6M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCT
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
